In a follow-up study, they showed that monocytes from untreated MS patients exhibit an overexpression of activation markers—such as CD40, CD86, HLA-DR, CD64, and CCR2—suggesting a heightened state of activation, and these cells are predominantly CD16+ [28]. This evidence concerns the gene CCR2 and myeloid sarcoma.